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Abstract
Background: Rare diseases are individually rare but globally affect around 6% of the population, and in over 70%
of cases are genetically determined. Their rarity translates into a delayed diagnosis, with 25% of patients waiting 5
to 30 years for one. It is essential to raise awareness of patients and clinicians of existing gene and variant-specific
therapeutics at the time of diagnosis to avoid that treatment delays add up to the diagnostic odyssey of rare
diseases’ patients and their families.
Aims: This paper aims to provide guidance and give detailed instructions on how to write homogeneous
systematic reviews of rare diseases’ treatments in a manner that allows the capture of the results in a computer-
accessible form. The published results need to comply with the FAIR guiding principles for scientific data
management and stewardship to facilitate the extraction of datasets that are easily transposable into machine-
actionable information. The ultimate purpose is the creation of a database of rare disease treatments
(“Treatabolome”) at gene and variant levels as part of the H2020 research project Solve-RD.
Results: Each systematic review follows a written protocol to address one or more rare diseases in which the
authors are experts. The bibliographic search strategy requires detailed documentation to allow its replication. Data
capture forms should be built to facilitate the filling of a data capture spreadsheet and to record the application of
the inclusion and exclusion criteria to each search result. A PRISMA flowchart is required to provide an overview of
the processes of search and selection of papers. A separate table condenses the data collected during the
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Systematic Review, appraised according to their level of evidence.
Conclusions: This paper provides a template that includes the instructions for writing FAIR-compliant systematic
reviews of rare diseases’ treatments that enables the assembly of a Treatabolome database that complement
existing diagnostic and management support tools with treatment awareness data.
Keywords: Rare diseases, Systematic literature reviews, Treatment knowledge-base
Background
In Europe, rare diseases (RD) are defined as those that
affect one in two thousand individuals or fewer. Globally
they affect around 6% of the population, and this means
that, collectively, healthcare providers deal with a con-
siderable number of patients with a rare disease, of
which over 70% are genetically determined [1, 2]. A re-
cent calculation of the cumulative prevalence at a global
level based on the Orphanet epidemiology data file esti-
mates that, regarding the 2017 population, there is a
minimum prevalence of 3.5–5.9%, which corresponds to
263–446 million persons affected worldwide [2]. The
problem is that each of those patients has a condition
that they share with only a small number of individuals
locally and sometimes even globally. For this reason, it is
difficult to ensure that patients can access the right med-
ical expertise as doctors seldom see such cases, and this
fact contributes to a delay in diagnosis. A survey has
shown that for a representative sample of 8 rare diseases,
25% of the patients wait 5 to 30 years to have a diagno-
sis, and 40% receive a wrong diagnosis before the final
one [3, 4]. Living with a rare disease is a challenge and
the lack of diagnosis – either because one exists but has
not been identified for a particular patient or because
the patient has a “syndrome without a name” (SWAN) –
is a cause of extreme stress for patients and their fam-
ilies. In 2016, in an effort to help those undergoing the
“diagnostic odyssey”, a group of rare disease organisa-
tions issued recommendations to address the specific
needs of undiagnosed rare disease patients [4]. These in-
clude recognition as a distinct population, support
through national and international programmes in which
patients and their advocates are directly involved, and
ethical international data sharing that accelerates
innovation and discovery. International consortia
(UDNI, IRDiRC) aim towards the next steps and strat-
egies finding a diagnosis also in patients who already
had comprehensive genetic testing [5]. Clinical research
in these patient populations is also a challenge, as it re-
quires the specific features of the rare disease to be ad-
dressed and often requires patient numbers that cannot
be obtained in one clinic or country [3]. Only inter-
national collaboration can shorten the diagnostic delay
and gather the cohorts required for clinical research by
enabling the sharing of resources and data in an ethical
manner that protects patients’ confidential data while
enabling research and pooling of expertise.
Another issue has to do with treatment delay. Al-
though rare diseases treatments are still scarce, the
existing ones are sometimes overlooked as a conse-
quence of that rarity and its application may be de-
layed. This is particularly true for variant and
mutation-specific treatments as the ones for Congeni-
tal Myasthenia Syndromes [6].
In the current paper, we propose a common method-
ology for developing systematic literature reviews feed-
ing into an innovative concept of a knowledge base of
rare diseases’ treatments, as part of the European project
Solve-RD. “Solve-RD - solving the unsolved rare dis-
eases” is a research project funded under the European
Union’s Horizon 2020 research and innovation
programme (2018–2022). It echoes the ambitious goals
set out by the International Rare Diseases Research Con-
sortium (IRDiRC) to deliver by 2020 diagnostic tests for
most rare diseases and 200 new therapies [the latter
achieved 3 years ahead of schedule [7]], as the current
diagnostic and subsequent therapeutic management of
rare diseases is still highly unsatisfactory for a large pro-
portion of patients – the unsolved RD cases. The con-
cept behind Solve-RD is therefore to promote the
diagnosis of cases by an integrated “beyond the exome”
approach that combines Omics and generates a “genetic
knowledge web” improving the diagnostic yield for rare
disease patients. Solve-RD develops mechanisms for en-
suring patients solved through this project are put on
the precise path for appropriate therapy and further re-
search. This aim will be served by the production of a
publicly-available “Treatabolome” knowledge base to en-
able the flagging of treatable genes and variants to the
sample-submitting clinician and at the same time identi-
fying patient cohorts and bio-samples availability for
clinical research. A substantial proportion of treatments
that are already available for rare diseases are only suit-
able for patients with a particular genetic defect, as ex-
emplified in a recent paper for Congenital Myasthenic
Syndromes [6], and with the coming era of personalised
medicine, this number is expected to grow. Enabling the
flagging of treatable genes and variants to the clinician
analysing the case means that the patient can be assessed
for the relevant treatment the moment diagnosis is
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reached. The Treatabolome will thus enhance the visibil-
ity and accessibility of rare disease therapies (Fig. 1).
This is needed as only 6% of the rare diseases have a
known treatment at present [8] and clinicians are often
not immediately aware of a gene or variant-specific
treatment and can only discover this information after a
relatively onerous search of the literature. The Treatabo-
lome complements the omics approach to diagnosis by
adding an innovative therapeutic information branch
pointing to gene and variant-specific treatments.
Our goal with the Treatabolome is to make this infor-
mation more readily and immediately accessible. In
order to be founded on the best evidence available, it
must still begin with an analysis of the literature, but by
producing a systematic review that gathers the informa-
tion in a computer-accessible manner that can be used
for the assembly of the Treatabolome database, we can
reduce the work that clinicians must do to find the in-
formation in future. A Solve-RD task force is currently
working towards building that database by working with
disease experts to manually capture gene and variant in-
formation from the literature by means of a systematic
literature review, mapping it to existing phenotype, gene
and classification ontologies and correlating it to existing
specific therapies in a database developed by computer
experts (Fig. 2). Although previous systematic reviews
have been written about rare diseases and genetic condi-
tions, the singularity of the Treatabolome is that they
are centred on gene and variant specific treatments and
will translate into a precision medicine endeavour. The
Treatabolome systematic reviews will share a common
research question and are expert-led with direct involve-
ment of specialists in each rare disease area, starting by
experts from the four European Reference Networks [9]
that participate in Solve-RD. However, our aim is to
reach out to every ERN and invite experts from around
the world to take the lead in their area of expertise.
It is not hard to anticipate that in the future the sus-
tainability of this project will depend on a “big data to
knowledge” (BD2K) methodology that uses text-mining
of scientific publications for accruing and updating the
knowledge database [10]. Therefore, the task force is
working on a pilot of a text-mining tool to serve that
purpose.
Aims
The present paper aims to lay out the common ground
and rules for all the Treatabolome expert-led systematic
literature reviews (SLR) and incentivise the adoption of
the FAIR-guiding principles for scientific data manage-
ment and stewardship [11] as that later facilitate the
translation of human-readable scientific papers into
computer-actionable data. Under these FAIR principles,
the data and metadata required for the translation of
content, tools, algorithms, consents, and workflows de-
scribed in the systematic reviews are collected into
transparent, reproducible, and reusable digitally-
accessible datasets. Based on the interpretation of
metadata, digital devices can take appropriate action on
approved areas without the need for direct human inter-
vention, a state denominated “machine-actionability.”
Such digital resources can autonomously determine how
Fig. 1 The Treatabolome is a project aiming at collecting and making freely available information about gene and variant-specific treatments for
rare diseases. It starts by selecting a disease (or disease-group of interest) of interest and running a systematic literature review to identify the
gene and variant-specific treatments that have been published. The resulting datasets will comply to the FAIR guiding principles of data
stewardship to enable its easy translation to machine-readable data elements. The resulting database will be freely available online and will be
made available for integration into existing diagnosis and management support tools, e.g. the GPAP platform of RD-Connect
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to act when presented with an unknown digital object as
they are capable of determining the structure, reusability
and intent of the object, through the interpretation of li-
cense, consent, and other data use constraints. These
mechanisms enable the computer to “judge” if specific
data can be shared, to give an example of machine ac-
tionable application.
The FAIR-compliant systematic reviews for rare dis-
eases’ treatments will feed the Treatabolome database to
enable expertise sharing. The aim is to increase treat-
ment visibility by flagging existing rare diseases’ gene
and variant-specific treatments each time a diagnosis is
reached, through the incorporation of the Treatabolome
datasets into diagnosis and management support tools.
Methods
The starting point within the Treatabolome task is to
engage clinical experts in the production of state-of-the-
art systematic reviews of specific treatments for the rare
diseases of their expertise. The critical addition to the
workflow, in comparison with a traditional systematic
review, is the capture of evidence linking treatment with
specific genotype to enable the creation of a Treatabo-
lome database flagging potentially treatable genes and
variants. This information is mapped to different ontol-
ogies and classification systems. A checklist with recom-
mendations has been composed to assist with the
harmonisation of the different Treatabolome systematic
reviews (Fig. 3). We describe below the proposed
methodology for these SLRs, including an explanation of
the checklist recommendations.
Systematic review protocol
The systematic reviews should follow a written “System-
atic Review Protocol” (Additional file 1) based on the
PROSPERO template from the Centre for Reviews and
Dissemination [12]. The advantage of using a
PROSPERO-inspired protocol is that it was explicitly de-
signed for Systematic Literary Reviews (SLR) and identi-
fies the major information items that are relevant for the
full documentation and validation of the SLR. It includes
administrative and general information entries, methods
items, and process indicators. This framework promotes
transparency and accountability to SLR registered at the
PROSPERO website, which is optional for the Treatabo-
lome contributors.
Figure 4 depicts the details of some of the protocol
steps and how they articulate with the different phases
of the Systematic Review. A more detailed description
can also be found below.
Systematic review research question
Having found a disease or set of diseases on which to
dedicate the systematic literature review (SLR), the next
step consists of elaborating the systematic review research
question, which is the starting point for any SLR that
seeks an answer by identifying all relevant studies, per-
forming quality of evidence appraisals and summarising
Fig. 2 The Treatabolome is a precision medicine project. Departing from deep phenotyping using HPO terms it makes the correspondence with
the causative gene variant designated according to HGVS convention, enabling a precise ORDO classification of the condition. If described, the
Treatabolome will point the corresponding gene and variant-specific treatment. ORDO – Orphanet Rare Diseases Ontology. HPO – Human
Phenotype Ontology. HGVS – Human Genome Variation Society. GPAP – Genome-Phenome Analysis Platform from RD-Connect
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Fig. 3 The Treatabolome Systematic Review Checklist
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quantitatively or qualitatively the evidence. We have elab-
orated a common research question to serve all the treta-
bolome systematic reviews:
“What treatments have been described for this
condition/gene/variant; on which specific genetic
variants have they been tested; and what is the
strength of the associated supporting evidence?”
The question does not address only general treatment
considerations but, more specifically, looks for
treatments tested for specific genetic causes, which
allows to establish gene and variant-specific treatment
reports. Whenever this is not possible, other treatment-
meaningful genotype-phenotype associations are
captured through the integration of the Treatabolome
database with other existing resources.
Search strategy
There is a need to build a search strategy and choose
the databases/sources to be inquired to find the answers
for the research question. Some examples of databases
commonly employed are:
 PubMed
 The Cochrane Central Register of Controlled Trials
(CENTRAL)
 ClinicalTrials.gov
 WHO International Clinical Trials Registry Platform
(https://www.who.int/ictrp/en/)
 European Clinical Trials Database (EudraCT)
https://eudract.ema.europa.eu
The usual number of searched databases is between 1
to 5. The detailed documentation of the search process
requires the production of a Search Log to enable repli-
cation of the Search Strategy. A Search Log is a docu-
ment that indicates the date of search, the database or
databases queried, the precise search terms and expres-
sions employed, and the number of results returned. Ex-
amples of search logs are available online [13], some in
spreadsheet format [14], and Additional file 2 contains a
Search Log template for exemplification.
Once the list of publications is gathered through the
searches reported above, it is advisable to import the re-
sults into a bibliography software package that will assist
with the exclusion of duplicated references, an essential
step before starting the data capture phase. One can also
export the list into a spreadsheet and exclude duplicated
entries in the spreadsheet software. The spreadsheet list
is commonly called the journal citation report and
Fig. 4 Systematic Review phases: the processes described in the checklists are here expressed in their timeline allocation for the different phases
of the Treatabolome Systematic Review process. ChEBI Chemical Entities of Biological Interest. DRON – Drug ontology mapped to RxNorm and
ChEBI. GRADE - Grading of Recommendations, Assessment, Development and Evaluations is a transparent framework for developing and
presenting summaries of evidence and provides a systematic approach for making clinical practice recommendations. HGVS – Human Genome
Variation Society. HPO – Human Phenotype Ontology. OCEBM – Oxford Clinical Eviodence-Based Medicine levels. OMIM - Online Mendelian
Inheritance in Man (omim.org). ORDO – Orphanet Rare Diseases Ontology
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collates the information extracted from the bibliography
or reference management software organised by fields.
This tool is useful to document the rating of papers ac-
cording to the inclusion and exclusion criteria, evidence
level and other, and provides the accounting for papers
excluded and included in the review.
Data capture
The selected references need to be reviewed, initially by
title and abstract analysis followed by full-test analysis
whenever necessary. A data capture form based on a
Cochrane Collaboration Template is supplied to docu-
ment the application of inclusion and exclusion criteria
and the selection of papers (Additional file 3). When
compared to the spreadsheet headings in Table 1, it
appears that the data capture form is much more com-
plex, which implies the need to tailor it to the specific
needs of the selected disease groups instead of using it
regardless. The Treatabolome systematic reviews have
broad Inclusion criteria that tolerate all kinds of re-
search, as investigation in rare diseases is usually scarce.
The systematic reviews need to accommodate everything
from case reports of treatment effects up to double-
blind randomised controlled trials, but that inclusiveness
has to be tempered by the careful and expert appraisal
of the evidence level of the collected data. It is a fact that
patients and relatives have long waited for therapies to
arrive. This may generate unrealistic expectations about
any emerging treatment and requires careful manage-
ment by clinicians. The assessment of the level of
Table 1 Codebook specifying data capture form spreadsheet headings
Item Variable name Value label
Identification of publication pmid PubMed Identifier is a unique integer value assigned to each PubMed
abstract record (to be distinguished from PMCID that corresponds to
full-text records in PMC)
Identification of publication doi The Digital Object Identifier from the International DOI Foundation is a
generic framework for managing identification of content over digital
networks.
Identification of publication harvard Use a full reference in Harvard style as described in
https://www.mendeley.com/guides/harvard-citation-guide. Include a full
url to the journal homepage each time a DOI and PMID do not exist by
searching the url on the NLM catalog online
(https://www.ncbi.nlm.nih.gov/nlmcatalog)
Year of publication year
Authors authors
Title of Publication title
Journal of publication journal
Full abstract abstract
Phenotype of a group of rare diseases gener_pheno Rare diseases phenotypical grouping, e.g. Congenital Myasthenic
Syndromes CMS
Specific phenotype unde the generic phenotype specific_phenotype e.g. DOK7-related CMS form under CMS
Type of study study_type case, series, cohort, non-controlled trial, randomised controlled trial, double
blind randomised controlled trial, other
Number of patients patients_num
Gene gene
Subtype descriptive name subtype_name
Subtype OMIM code subtype_OMIM
Variants variants
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evidence supporting each treatment assists clinicians in
explaining what realistic outcomes can be expected from
treatments.
Inclusion criteria
Peer-reviewed papers in english language, reporting
treatment at gene or gene variant levels, no matter the
dimension of the population (case, series, cohort or
other study population), the timeline of the study (retro-
spective or prospective), the existence of comparator (no
comparator, compared against natural history, cohort
study, matched control group), with or without rando-
misations and with or without blinding. An accurate de-
scription of all the characteristics of the study, namely
the processes of randomisation and blinding, when exist-
ing, assists the accurate appraisal of evidence. Outcomes,
qualitative or quantitative, should be mentioned with the
intervention.
Exclusion criteria
Cases without therapeutic intervention or regarding gen-
eric therapeutic interventions (e.g, the benefit of physio-
therapy for a diverse group of patients) should be
excluded. Studies that do not report outcomes should
only be discussed in the narrative summary but not
counted as evidence for the systematic review.
The data capture form identifies the publication with-
out ambiguity resorting to DOI and PMID pointers and
using Harvard style citations of the paper. Cases without
DOI or PMID have to include a URL address collected
from the NLM online catalogue (https://www.ncbi.nlm.
nih.gov/nlmcatalog) that indicates the web address of
the publication’s journal. Further instructions on how to
format the bibliographic entries according to Harvard
format can be retrieved online (https://www.mendeley.
com/guides/harvard-citation-guide), although it may be
easier to import all the publications into a bibliography
software that formats the references into Harvard mode.
A title and abstract scan allow to select the papers for
a full-text review. Papers with specific treatments for
identified genes or variants of genes are the main feeders
of these systematic reviews. Studies with the selected
sensible target disease(s) are to be searched for an indi-
cation of gene and variant information and data on in-
heritance and zygosity before recording the reportedly
used drugs, their effects, adverse events or contraindica-
tions. Excluded papers should have the exclusion reason
documented in a field. The annotations of the papers se-
lected for inclusion include mention to the type of study
described, the number of patients involved, the existence
of a control group, randomisation and blinding, docu-
menting the implementation of the latter. A common re-
quirement for all the systematic reviews is that the
selection and review of papers are graphically depicted
using a PRISMA flowchart [15]. A template is supplied
in Additional file 4 and further clarification on its use
can be found on the PRISMA website (http://prisma-
statement.org/PRISMAStatement/FlowDiagram.aspx).
The PRISMA flowchart depicts the number of papers
that were dealt with during the Identification, Screening,
Eligibility and Inclusion phases of the review process.
The existence of the documentation mentioned above
determines the trustworthiness of the systematic reviews
by building an audit trail that enables replication of
results.
Data extraction
Data extraction aggregates data in meaningful bundles
for analysis, guided by the protocol’s inclusion and
exclusion criteria. The process follows the data cap-
ture form carefully and later transferred to a data
capture table built on the template codebook in Table
1. Most of the time the populations of interest are
extractable based on phenotypic and genetic charac-
terisation, treatment employed and observed effects.
However, whenever doubts and divergences emerge
regarding inclusion and exclusion of research papers,
the arbitration mechanism has to be described at
length in the protocol, naming who are the reviewers
and who is designated to arbitrate in cases where re-
viewers’ unanimity cannot be reached.
All treatments tried for a specific gene variant need as
detailed supporting evidence as possible regarding ef-
fects, adverse events and contraindications. In cases
where treatment is a pharmacological drug, its un-
equivocal identification requires clarification by adopting
ChEBI nomenclature (https://www.ebi.ac.uk/chebi/init.
do). A systematic review frequently returns results of
multiple different treatment options, some useful under
different circumstances, others ineffective or harmful.
All of these possibilities should be captured in the out-
put, as they are all of relevance to clinical decision-
making. First-line treatment and alternative options
should be presented in clear terms when possible.
Weight of evidence may favour a specific treatment as
first-line therapy, or a particular therapy may generally
be used as adjunctive or as an alternative under certain
circumstances. It is necessary to differentiate all these
options and map them to the corresponding evidence.
Patients with rare diseases are often risk-takers as a
consequence of the scarcity of innovation and research
in rare disease areas. For patients’ safeguard, the Treata-
bolome opts for using a transparent and sensible ap-
proach for grading the quality of evidence and strength
of recommendations in health care. This choice reflects
our vision that is centred on the clinical significance of
the findings and not exclusively on the statistical signifi-
cance or effects size. We believe that is the right focus
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for establishing a health technology assessment for these
treatments in a hopefully near future.
We adopted the GRADE methodology for appraising
the evidence collected and reaching the Treatabolome
database treatment recommendations. The GRADE
questionnaire is part of the Data Capture form supplied
and is also available online through a resource that is
free for academic institutions, the GRADE Pro website
(https://gradepro.org). An online handbook and other
resources are available at the website to support users
(https://gdt.gradepro.org/app/handbook/handbook.
html).
The Oxford Centre for Evidence-Based Medicine has
issued Levels of Evidence to assist in the appraisal of
published scientific evidence (http://www.cebm.net/
index.aspx?o=5653). This helpful tool allows for a quick
overview of data quality and its parallel use reinforces
the objectivity of the Treatabolome recommendations.
Other tools can also be considered like the Jadad Score
[16], although the latter is applied for appraising clinical
trials and these are scarce in the rare diseases’ field.
Data synthesis
The synthesis phase follows the extraction phase, and it
addresses the quantitative and qualitative aspects separ-
ately. The qualitative analysis employs different tools de-
pending on the objectives of the systematic review [17]:
 narrative analysis extracts key concepts from a study
 narrative summary does a textual combination of
data, namely when qualitative studies are
heterogeneous (meta-synthesis)
 meta-ethnography synthesises the qualitative data to
reach new theoretical understandings.
The synthesis of quantitative data differs depending on
the heterogeneity of studies. The meta-analysis, an oper-
ation that combines data from different studies, should
only be performed if data from intervention studies are
similar, and it is sensible to combine the studies. When
it is feasible, meta-analysis enhances the degree of cer-
tainty when answering a research question as it boosts
the power of data by aggregation of datasets [18]. Details
about the sophisticated meta-analysis methodology are
beyond this paper’s scope and so the reader is referred
to existing quality resources if necessary [19, 20].
The majority of rare diseases’ treatment publications
are single case or case series-reports, having a low-
evidence level, high heterogeneity of methods, and fre-
quently using no comparators or only historical ones.
On the other hand, as the objective is to identify gene
and variant-specific treatment reports it is harder to
identify homogeneous studies on which to perform a
meta-analysis, as studies are both scarce and
heterogeneous regarding populations, methodologies or
interventions. Gathering conditions to perform a meta-
analysis in this scenery is therefore unlikely. Considering
the above limitations, it is fortunate that data synthesis
still brings enlightenment by aggregating data in tables,
performing a narrative summary and counting the pa-
pers reporting a similar effect. The structure of this sum-
mary is essential and should be planned. In the current
project, the decisions regarding reporting are discussed
in the protocol of the systematic review and data synthe-
sis should follow the spreadsheet template provided as
codebook in Table 2. Consequently, the authors of the
systematic review should try when possible to indicate
the first line of treatment and potential alternatives for
each genotype and indicate the corresponding level of
evidence for each of the treatment modalities. As treat-
ments may already have marketing authorizations, usu-
ally for other conditions, details of the authorization
should also be captured and discussed in terms of access
to therapy and orphan drug designation.
Discussion
The Treatabolome concept fills in a missing link in the
existing diagnostic support tools, enabling the existing
treatments for rare diseases to have maximal visibility to
avoid adding treatment delay to the rare disease diagnos-
tic odyssey that often deprives patients and families of
diagnosis over a significant time. The Treatabolome pro-
ject fulfils that objective by liaising with existing diag-
nostic and support tools and providing treatment
information at the gene and variant level whenever pos-
sible. Immediate treatment visibility at the moment of
diagnosis is the primary goal of the project and to trigger
it full Systematic Literature Reviews must supply the
expert-reviewed information. The continuous update of
this information requires recurrent scanning of the lit-
erature that may in the future depend on text-mining of
scientific papers instead of repeated expert-led literature
reviews. The experts that are part of the four participat-
ing European Reference Networks of the Solve-RD Euro-
pean Project were invited to cooperate on the
Treatabolome tasks ahead of others. Still, the natural
evolution of the task presupposes the growing involve-
ment of a multitude of experts across the world.
Conclusions
In general, systematic reviews are still the best tool to
guarantee that decisions regarding healthcare and re-
search are guided by the best existing evidence to pro-
vide the best possible care to patients. Despite the efforts
done for automation of systematic reviews [21, 22], the
process is still mostly dependent on human effort, and
the Treatabolome ones are characterised by the extra
challenge of trying to find gene and variant-specific
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treatments while appraising their level of evidence
through consecrated tools, as the GRADE system and
the Oxford Evidence-Based Medicine Levels. It is our
hope that the current paper assists researchers in devel-
oping Treatabolome systematic reviews and producing
datasets for future incorporation in the Treatabolome
knowledge base and diagnostic support tools.
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1186/s13023-020-01493-7.
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Table 2 codebook specifying summary table column headings (variable names)
Item Variable name Value label
Phenotype of a group of rare diseases gener_pheno Rare diseases phenotypical grouping, e.g. Congenital Myasthenic
Syndromes CMS
Specific phenotype under the generic phenotype spec_pheno Rare diseases subtype under a generic phenotype, e.g. DOK7
under CMS
Gene gene
First-line treatment recommendation first_line
Alternative treatment 1 alt_treat_1
Alternative treatment 2 alt_treat_2
Likely innefective innefective List of medications tried without success
Harmful harmful List of medications that can harm these patients
Expert Summary of Evidence expert_sum
number of publications num_pub Integer that corresponds to the total of publications reviewed for
this database entry
Key reference key_ref Main literature reference for the database entry
PMIDs pmids List the PMIDs of papers referenced for this database entry
DOIs dois List of DOIs of papers referenced for this database entry
OCEBM ocebm OCEBM classification of evidence
GRADE grade GRADE classification of evidence
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